Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00689936 · ClinicalTrials.gov registry record · Phase 3
Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma
A Phase 3 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,623
- Enrollment target
NCT00689936 is a Phase 3 study that has completed, run by Celgene. The registered enrollment target is 1,623 participants.
The verdict
NCT00689936, a Phase 3 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,623 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the safety and efficacy of Lenalidomide plus low dose dexamethasone to that of the combination of melphalan, prednisone and thalidomide.
Interventions
- DRUG Lenalidomide and low-dose dexamethasone
- DRUG Lenalidomide plus low-dose dexamethasone given for 18 four-week cycles
- DRUG Melphalan, Prednisone and Thalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,623 participants |
| Start Date | 2008-08-21 |
| Est. Completion | 2016-07-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00689936
The ClinicalTrials.gov registry entry for NCT00689936 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,623 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Lenalidomide and low-dose dexamethasone is the first listed.
NCT00689936 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00689936 about?
NCT00689936 is a clinical study titled "Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma". The purpose of this study is to compare the safety and efficacy of Lenalidomide plus low dose dexamethasone to that of the combination of melphalan, prednisone and thalidomide.
What is the current status of trial NCT00689936?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,623 participants. The study started on 2008-08-21. Estimated completion is 2016-07-14.
What interventions are being tested in trial NCT00689936?
The interventions under investigation include: Lenalidomide and low-dose dexamethasone (DRUG), Lenalidomide plus low-dose dexamethasone given for 18 four-week cycles (DRUG), Melphalan, Prednisone and Thalidomide (DRUG).
Who is sponsoring clinical trial NCT00689936?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.